S&P 500 7,490 +1.05% Nasdaq 25,374 +1.59% Dow Jones 52,485 +1.04% FTSE 100 10,868 +1.23% DAX 25,629 +2.11% Nikkei 225 63,342 +1.57% Hang Seng 25,842 +2.52% WTI Crude 80.21 +1.20% Gold 4,111 +1.85% US 10-Year Treasury Yield 4.745 +2.24% S&P 500 7,490 +1.05% Nasdaq 25,374 +1.59% Dow Jones 52,485 +1.04% FTSE 100 10,868 +1.23% DAX 25,629 +2.11% Nikkei 225 63,342 +1.57% Hang Seng 25,842 +2.52% WTI Crude 80.21 +1.20% Gold 4,111 +1.85% US 10-Year Treasury Yield 4.745 +2.24%

LATEST

ETMarkets Smart Talk | Manufacturing and financialisation could create the most wealth over the next five years: Siddhartha Khemka●Manipal Health Enterprises IPO allotment likely today: How to check status, GMP, listing date, key details●Positive Breakout: These 7 stocks cross above their 200 DMAs●US and Japan jointly intervene to prop up yen in rare move●Nifty 50, Sensex prediction today: Check how Indian stock market is expected to trade on 3 August●Will new batteries give China’s EVs the jolt they need to charge past their rivals?●UAE to revamp crude pricing amid sharp market fluctuations●Gold gains as oil slumps after Trump holds off on Iran attack●ETMarkets Smart Talk | Manufacturing and financialisation could create the most wealth over the next five years: Siddhartha Khemka●Manipal Health Enterprises IPO allotment likely today: How to check status, GMP, listing date, key details●Positive Breakout: These 7 stocks cross above their 200 DMAs●US and Japan jointly intervene to prop up yen in rare move●Nifty 50, Sensex prediction today: Check how Indian stock market is expected to trade on 3 August●Will new batteries give China’s EVs the jolt they need to charge past their rivals?●UAE to revamp crude pricing amid sharp market fluctuations●Gold gains as oil slumps after Trump holds off on Iran attack●

Asia

MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline

Markets-Economic Times · 1h ago · 🇮🇳 India

MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline

Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.

Read the full story at Markets-Economic Times →

More Asia

ETMarkets Smart Talk | Manufacturing and financialisation could create the most wealth over the next five years: Siddhartha Khemka

Markets-Economic Times · 41m ago

Manipal Health Enterprises IPO allotment likely today: How to check status, GMP, listing date, key details

Markets-Economic Times · 41m ago

Positive Breakout: These 7 stocks cross above their 200 DMAs

Markets-Economic Times · 49m ago

Nifty 50, Sensex prediction today: Check how Indian stock market is expected to trade on 3 August

mint - markets · 51m ago